Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/20072
RANDOMIZED, DOUBLE-BLIND STUDY OF STIBOGLUCONATE PLUS HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR VERSUS STIBOGLUCONATE ALONE IN THE TREATMENT OF CUTANEOUS LEISHMANIASIS
Gluconato de antimônio e sódio
Agentes antiprotozoários
Fator Estimulador de Colônia de Granulócitos
Criança
Humanos
Antimony Sodium Gluconate
Antiprotozoal Agents
Granulocyte-Macrophage Colony-Stimulating Factor
Child
Humans
Autor(es)
Afiliação
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Cornell University Medical College. NY Hospital. Division of International Health and Infectious Diseases. Department of Medicine. New York, NY
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Cornell University Medical College. NY Hospital. Division of International Health and Infectious Diseases. Department of Medicine. New York, NY
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Cornell University Medical College. NY Hospital. Division of International Health and Infectious Diseases. Department of Medicine. New York, NY
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Cornell University Medical College. NY Hospital. Division of International Health and Infectious Diseases. Department of Medicine. New York, NY
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Resumo em Inglês
The response to recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis was evaluated. Twenty patients with cutaneous leishmaniasis who had lesions for 60 days were enrolled in a double-blind placebo trial of GM-CSF with standard parenteral sodium stibogluconate (20 mg/kg-1/day-1) for 20 days. Ten patients were randomized to receive intralesionally injected GM-CSF (200 microgram) at enrollment and 1 week after, and 10 patients received saline as placebo. GM-CSF- and antimony-treated patients healed faster than patients who received antimony alone (49+/-32.8 vs. 110+/-61.6 days, P<.05). Seven of 10 patients were healed of their lesions before 40 days after therapy in the GM-CSF group, compared with only 1 of 10 patients in the placebo group (relative risk, 7; 95% confidence interval, 1.04-47.00). Thus, GM-CSF plus antimony significantly increased the chance of lesion healing in 40 days.
Palavras-chave
Leishmaniose cutâneaGluconato de antimônio e sódio
Agentes antiprotozoários
Fator Estimulador de Colônia de Granulócitos
Criança
Humanos
Palavras-chave em inglês
Leishmaniasis, CutaneousAntimony Sodium Gluconate
Antiprotozoal Agents
Granulocyte-Macrophage Colony-Stimulating Factor
Child
Humans
Compartilhar